This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lynne Lamberg
JAMA contributor

JAMA. 1998;280:953-954.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

SECOND-GENERATION medications for schizophrenia, introduced in the United States in 1990, have brought some benefit to most patients and dramatic improvement to a few, prompting cautious optimism about a better future for the 2 million Americans estimated to have this severe disorder, according to talks at the annual meeting of the American Psychiatric Association (APA) in Toronto, Ontario, and interviews with experts in the field.

"The incremental improvements are significant enough that many persons with schizophrenia are able to come back into society," said Richard Jed Wyatt, MD, chief of the Neuropsychiatry Branch of the National Institute of Mental Health, Bethesda, Md. "If we can keep people out of hospitals 5 to 10 days a year," he asserted, "we easily can cover the roughly $2000 cost of an entire year's medication."

Schizophrenia costs the United States $65 billion a year, Wyatt said, with $19 billion spent on direct . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The psychopathology, medical management and dental implications of schizophrenia
FRIEDLANDER and MARDER
Journal of the American Dental Association 2002;133:603-610.
ABSTRACT | FULL TEXT